Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs in RDEB
NCT02323789Phase 2Unknown
- Sponsor
- King's College London
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tonsil-derived mesenchymal stem cells in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by King's College London. Primary endpoint: Lack of serious and severe adverse events at 12 months. Status: unknown.
02
Drugs
tonsil-derived mesenchymal stem cells
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT02323789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323789.